Jason Goldstein

Re-Aim Therapeutics is redefining how autoimmune diseases are treated by selectively depleting the pathogenic T cell subsets that drive chronic inflammation, autoimmunity and disease progression. By integrating human pathway signatures and transcription factor-linked membrane targets, we pinpoint the precise T cell coordinating and maintaining the autoimmune responses. By drugging precise target epitopes in their functional state and within the relevant disease context, we achieve a level of selectivity that conventional expression profiling and engineering approaches cannot reach. Our mission is to deliver functional cures across a broad spectrum of autoimmune conditions. We are a team with exceptional antibody discovery and development expertise, world‑class scientific advisors, and committed investors, all aligned around rigorous execution and transformative impact.

Developing first-in-class LRG inhibitor to harness pathogenic effect of TGF-β cascade in chronic kidney disease and cancer | a spin-out from University College London

In stealth mode.

Lightox has developed a new drug for the treatment of early stage oral cancers. The topically applied formulation allows for specific delivery to the lesion and is activated by a specific wavelength of light.

Our mission at Abselion is to simplify protein quantification for the scientists making crucial decisions to accelerate the development of biotherapeutics. Our tools help researchers to develop the medicine of the future and to find the best ways to produce new biomolecules. We focus on convenient tools with high degree of automation and low hands-on time to accelerate access to actionable data. Our award-winning Amperia system, built on proprietary Redox Electrochemical Detection (RED) technology, brings a new approach to biologics and viral-vector quantification for confident and cost-effective automated, at-line titre measurement, at any bench or bioreactor. By enabling agile and straightforward access to titre data, we empower scientists to focus on the decisions that can drive bioprocess optimisation and innovation. We are a dynamic, interdisciplinary team working at the intersection of biology, nanotechnology and data science. We value a flat hierarchy, where everyone is encouraged to share their ideas and to follow their passion.

Cellesce Ltd is a biochemical engineering company based in Cardiff in the UK. Cellesce specialises in the development, scale up and manufacture of organoids (PDOs).

Re-Aim Therapeutics is redefining how autoimmune diseases are treated by selectively depleting the pathogenic T cell subsets that drive chronic inflammation, autoimmunity and disease progression. By integrating human pathway signatures and transcription factor-linked membrane targets, we pinpoint the precise T cell coordinating and maintaining the autoimmune responses. By drugging precise target epitopes in their functional state and within the relevant disease context, we achieve a level of selectivity that conventional expression profiling and engineering approaches cannot reach. Our mission is to deliver functional cures across a broad spectrum of autoimmune conditions. We are a team with exceptional antibody discovery and development expertise, world‑class scientific advisors, and committed investors, all aligned around rigorous execution and transformative impact.

Developing first-in-class LRG inhibitor to harness pathogenic effect of TGF-β cascade in chronic kidney disease and cancer | a spin-out from University College London

In stealth mode.

Lightox has developed a new drug for the treatment of early stage oral cancers. The topically applied formulation allows for specific delivery to the lesion and is activated by a specific wavelength of light.